NCT04699968 is a Phase 2 clinical trial of SHR-1701，Famitinib in Non-Small-Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT04699968?

NCT04699968 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT04699968?

Interventions in NCT04699968: SHR-1701，Famitinib, SHR-1701.

What condition does NCT04699968 study?

NCT04699968 studies Non-Small-Cell Lung Cancer.

Is NCT04699968 still recruiting?

NCT04699968 is currently withdrawn. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT04699968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Withdrawn Phase 2 Last updated 7 June 2023

What this trial tests

Phase 2 trial testing SHR-1701，Famitinib in Non-Small-Cell Lung Cancer. Withdrawn.

Timeline

15 January 2021

Primary endpoint
15 November 2021

15 November 2021

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	15 January 2021
Primary completion	15 November 2021
Estimated completion	15 November 2021

Drugs / interventions tested

SHR-1701，Famitinib — full drug profile →
SHR-1701 — full drug profile →

Conditions studied

Non-Small-Cell Lung Cancer — all drugs for Non-Small-Cell Lung Cancer →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-Small-Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

TGF-beta signal transduction: biology, function and therapy for diseases.
Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials.
Li L, Wen Q, Ding R. · · 2022 · cited 17× · PMID 35957885 · DOI 10.3389/fonc.2022.905520
Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
Quach HT, Hou Z, Bellis RY, Saini JK, et al · · 2022 · cited 5× · PMID 36448335 · DOI 10.1080/13543784.2022.2152323
Current status and future perspectives of bispecific antibodies in the treatment of lung cancer.
Wang W, Qiu T, Li F, Ren S. · · 2023 · cited 4× · PMID 36848213 · DOI 10.1097/cm9.0000000000002460

Verify or expand the search:

Other recruiting trials for Non-Small-Cell Lung Cancer

Currently open trials in the same condition.

NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06574347 — Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. · Phase 2 · recruiting
NCT06476093 — SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer · NA · recruiting
NCT06015503 — A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metasta · Phase 2 · recruiting
NCT06343064 — Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI · Phase 1, PHASE2 · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04699968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04699968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing